 |
인쇄하기
취소
|
LGIS, Ildong to jointly develop hepatitis B drug
LG Life Sciences (LGLS) said Tuesday that it signed with Ildong Pharmaceutical to jointly develop a new hepatitis B drug ‘Besiforvir.’
According to LGLS which has completed the late-stage Phase II trial through its 10-year intensive studies, Besiforvir was shown to be an effective antiviral agent, capable of suppressing the hepatitis B virus with less serious renal and hepatic toxicity.
U...
According to LGLS which has completed the late-stage Phase II trial through its 10-year intensive studies, Besiforvir was shown to be an effective antiviral agent, capable of suppressing the hepatitis B virus with less serious renal and hepatic toxicity.
U...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.